CoChat
Sign Up
Cited by 10

The DOI matches its Crossref record.

Ipilimumab-associated cholestatic hepatitis: a case report and literature review

Yildirim, Sümeyra, Deniz, Kemal, Doğan, Ender, Başkol, Mevlüt, Gürsoy, Şebnem, Özkan, Metin·2017·Melanoma Research
DOI 10.1097/cmr.0000000000000366
Open this paper in CoChat — free account

Abstract

Ipilimumab is a monoclonal antibody that exerts its effects by inhibiting the cytotoxic T-lymphocyte-associated protein 4 receptor on cytotoxic T lymphocytes. It is frequently used for the treatment of unresectable or metastatic melanoma. Ipilimumab may lead to several immune-related disease including colitis, thyroiditis, pneumonia, hepatitis, or pancreatitis as a side effect. Limited number of cases with hepatic damage as an ipilimumab-related adverse event has been reported in the literature. This agent has been implicated in causing acute hepatitis-like liver injury. Here, we presented a case in which cholestatic hepatitis developed during ipilimumab use for the treatment of metastatic melanoma.

Overview

Integrity signals

Registry

Crossref · 10.1097/cmr.0000000000000366

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 5

  1. Kleiner, 2012, Pathologic changes in ipilimumab-related hepatitis in patients with metastatic melanoma, Dig Dis Sci, 57, 2233, 10.1007/s10620-012-2140-5 · DOI
  2. Kim, 2013, Ipilimumab associated hepatitis: imaging and clinicopathologic findings, Invest New Drugs, 31, 1071, 10.1007/s10637-013-9939-6 · DOI
  3. Cheng, 2015, Ipilimumab-induced toxicities and the gastroenterologist, J Gastroenterol Hepatol, 30, 657, 10.1111/jgh.12888 · DOI
  4. Johncilla, 2015, Ipilimumab-associated hepatitis: clinicopathologic characterization in a series of 11 cases, Am J Surg Pathol, 39, 1075, 10.1097/PAS.0000000000000453 · DOI
  5. Kleiner, 2017, The histopathological evaluation of drug-induced liver injury, Histopathology, 70, 81, 10.1111/his.13082 · DOI

Cited by

Sorted by citations

See all 10

Metadata

Authors
Yildirim, S., Deniz, K., Doğan, E., Başkol, M., Gürsoy, Ş., & Özkan, M.
Venue
Melanoma Research
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2017-08
Volume
27
Issue
4
Pages
380-382
ISSN
0960-8931
DOI
10.1097/cmr.0000000000000366
Cited by
10
References
0
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review